Clinical Trial Update: 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies [Phase 2]

View source ↗

Summary

Phase 2 study evaluating 18F-fluciclovine PET imaging in metastatic castration-resistant prostate cancer patients treated with life-prolonging therapies; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Sponsor: Tulane University | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-09-22